Neurotrophic Keratitis Treatment Market: Driving Growth with Emerging Therapies & Future Forecasts

The new report published by The Business Research Company, titled Neurotrophic Keratitis Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the neurotrophic keratitis treatment market size has grown strongly in recent years. It will grow from $4.7 billion in 2023 to $5.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The neurotrophic keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp

Rising Prevalence Of Eye Diseases Fuels Growth In The Neurotrophic Keratitis Treatment Market
The growing prevalence of eye diseases is expected to propel the growth of the neurotrophic keratitis treatment market going forward. Eye diseases are a wide range of medical problems and disorders that affect the structure and function of the eyes. Neurotrophic keratitis can aid in the improvement of corneal sensation, the promotion of healing, the prevention of infection, and the relief of pain and suffering. For instance, in March 2022, according to the reports shared by Eye Care One, a US-based eyecare career development services platform, it was estimated that 35 million US people will suffer from dry eye disease (DED) in 2022 and the prevalence will rise yearly. Furthermore, in March 2021, according to the Eyes of the World Foundation, a Spain-based non-profit organization, there will be 1.1 billion people with vision loss in 2021, which is estimated to increase to 1.7 billion by 2050. Therefore, the growing prevalence of eye diseases is driving the growth of the neurotrophic keratitis treatment market.

Innovative Drug Development Shapes The Landscape Of Neurotrophic Keratitis Treatment Market
Major companies operating in the neurotrophic keratitis treatment market are developing innovative drugs and getting them approved to uphold their market position. Drug development is vital in neurotrophic keratitis treatment as current treatments are limited and there is a need for more effective treatments to prevent the progression of the disease. For instance, in December 2022, BRIM Biotechnology Inc., a Taiwan-based clinical-stage company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for BRM424 for the treatment of neurotrophic keratitis (NK). It is a recombinant type of human nerve growth factor that stimulates the proliferation and differentiation of corneal limbal stem cells to regenerate and restore the cornea's health in patients with neurotrophic keratitis.

The neurotrophic keratitis treatment market covered in this report is segmented -

1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (rhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
2) By Route of Administration: Oral; Topical; Other Routes of Administration
3) By Application: Stage I; Stage II; Stage III
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12968&type=discount

Major players in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited.

Contents of the report:
1. Executive Summary
2. Neurotrophic Keratitis Treatment Market Report Structure
3. Neurotrophic Keratitis Treatment Market Trends And Strategies
4. Neurotrophic Keratitis Treatment Market - Macro Economic Scenario
5. Neurotrophic Keratitis Treatment Market Size And Growth
…..
27. Neurotrophic Keratitis Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.